Girard, Nicolas
Université de Versailles Saint-Quentin-en-Yvelines · Institut Curie
25 papers on CoChatORCID 0000-0001-9909-2299
Most cited papers
- Verified
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity
Cancer Immunotherapy and BiomarkersImmune cells in cancer
Cited by 5,870
- Verified
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 3,725
- Verified
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,201
- Verified
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine
Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations
Cited by 2,825
- Verified
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 2,546
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,256
- Verified
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell
Cancer Cells and MetastasisPluripotent Stem Cells Research
Cited by 2,180
- Verified
Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports
AI in cancer detectionCancer Immunotherapy and Biomarkers
Cited by 1,027
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 552
- Verified
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Courtiol, P., Maussion, C., Moarii, M., Pronier, E., Pilcer, S., Sefta, M., Manceron, P., Toldo, S., Zaslavskiy, M., Le Stang, N., et al. (2019) · Nature Medicine
AI in cancer detectionOccupational and environmental lung diseases
Cited by 544
- Verified
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports
Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research
Cited by 500
- Verified
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems
Cancer Genomics and DiagnosticsCancer-related Molecular Pathways
Cited by 431
- Verified
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal
Cancer Immunotherapy and BiomarkersInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Cited by 412
- Verified
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 399
- Verified
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Danlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer
Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions
Cited by 300
- Verified
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002
Couraud, S., Vaca-Paniagua, F., Villar, S., Oliver, J., Schuster, T., Blanché, H., Girard, N., Trédaniel, J., Guilleminault, L., Gervais, R., et al. (2014) · Clinical Cancer Research
Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations
Cited by 215
- Verified
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 198
- Verified
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 139
- Verified
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., et al. (2025) · New England Journal of Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 118
- Verified
Optimizing outcomes in EGFR Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?
Girard, N. (2018) · Future Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 103
- Verified
New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center
Galateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology
Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies
Cited by 93
- Verified
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., et al. (2025) · New England Journal of Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 70
- Verified
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., et al. (2020) · Frontiers in Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 52
- Verified
Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
Bilger, G., Toffart, A.-C., Darrason, M., Duruisseaux, M., Ulmer, L., Wang, P., Leprieur, E. G., Girard, N., Massiani, M. A., Bore, P., et al. (2022) · Therapeutic Advances in Medical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 15
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free